Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking.
Oncoimmunology
; 3: e28610, 2014.
Article
in En
| MEDLINE
| ID: mdl-25097801
ABSTRACT
Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast, we have reported that clinically active anti-human CD40 mAb CP-870,893 does not require FcR crosslinking, a finding with translational implications.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Oncoimmunology
Year:
2014
Document type:
Article